165 related articles for article (PubMed ID: 1464162)
1. In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.
Lee SM; Thatcher N; Crowther D; Margison GP
Cancer Chemother Pharmacol; 1992; 31(3):240-6. PubMed ID: 1464162
[TBL] [Abstract][Full Text] [Related]
2. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine.
Lee SM; Thatcher N; Margison GP
Cancer Res; 1991 Jan; 51(2):619-23. PubMed ID: 1824685
[TBL] [Abstract][Full Text] [Related]
3. Relationships between the formation of O6-methyldeoxyguanosine by 1-p-carboxyl-3,3-dimethylphenyltriazene in DNA and O6-alkylguanine-DNA alkyltransferase in human peripheral leukocytes.
Lee SM; O'Connor PJ; Thatcher N; Crowther D; Margison GP; Cooper DP
Cancer Res; 1994 Aug; 54(15):4072-6. PubMed ID: 8033139
[TBL] [Abstract][Full Text] [Related]
4. Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells.
Lee SM; Thatcher N; Dougal M; Margison GP
Br J Cancer; 1993 Feb; 67(2):216-21. PubMed ID: 8431354
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
Lee SM; Thatcher N; Crowther D; Margison GP
Br J Cancer; 1994 Mar; 69(3):452-6. PubMed ID: 8123472
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation.
Lee SM; Crowther D; Scarffe JH; Dougal M; Elder RH; Rafferty JA; Margison GP
Br J Cancer; 1992 Aug; 66(2):331-6. PubMed ID: 1387001
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
Lee SM; Margison GP; Woodcock AA; Thatcher N
Br J Cancer; 1993 Jun; 67(6):1356-60. PubMed ID: 8512821
[TBL] [Abstract][Full Text] [Related]
8. Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.
Lee SM; Margison GP; Thatcher N; O'Connor PJ; Cooper DP
Br J Cancer; 1994 May; 69(5):853-7. PubMed ID: 8180013
[TBL] [Abstract][Full Text] [Related]
9. Methyl DNA adducts, DNA repair, and hypoxanthine-guanine phosphoribosyl transferase mutations in peripheral white blood cells from patients with malignant melanoma treated with dacarbazine and hydroxyurea.
Philip PA; Souliotis VL; Harris AL; Salisbury A; Tates AD; Mitchell K; van Delft JH; Ganesan TS; Kyrtopoulos SA
Clin Cancer Res; 1996 Feb; 2(2):303-10. PubMed ID: 9816173
[TBL] [Abstract][Full Text] [Related]
10. Relationships among cell survival, O6-alkylguanine-DNA alkyltransferase activity, and reactivation of methylated adenovirus 5 and herpes simplex virus type 1 in human melanoma cell lines.
Maynard K; Parsons PG; Cerny T; Margison GP
Cancer Res; 1989 Sep; 49(17):4813-7. PubMed ID: 2547518
[TBL] [Abstract][Full Text] [Related]
11. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.
Baer JC; Freeman AA; Newlands ES; Watson AJ; Rafferty JA; Margison GP
Br J Cancer; 1993 Jun; 67(6):1299-302. PubMed ID: 8512814
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER; Middleton MR; Jones C; Olsen A; Hickson I; McHugh P; Margison GP; McGown G; Thorncroft M; Watson AJ; Boddy AV; Calvert AH; Harris AL; Newell DR; Curtin NJ
Clin Cancer Res; 2005 May; 11(9):3402-9. PubMed ID: 15867241
[TBL] [Abstract][Full Text] [Related]
13. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M
Ann Oncol; 1999 Jul; 10(7):831-8. PubMed ID: 10470431
[TBL] [Abstract][Full Text] [Related]
14. Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte 06-alkylguanine-DNA alkyltransferase activity.
Boiardi A; Silvani A; Ciusani E; Watson A; Margison G; Berger E; Lucas C; Giroux B
J Neurooncol; 2001 Apr; 52(2):149-56. PubMed ID: 11508814
[TBL] [Abstract][Full Text] [Related]
15. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.
Egyházi S; Margison GP; Hansson J; Ringborg U
Eur J Cancer; 1997 Jan; 33(1):129-34. PubMed ID: 9071912
[TBL] [Abstract][Full Text] [Related]
17. O6-alkylguanine-DNA alkyltransferase activity in human malignant melanoma.
Moriwaki S; Nishigori C; Takebe H; Imamura S
J Dermatol Sci; 1992 Jul; 4(1):6-10. PubMed ID: 1390458
[TBL] [Abstract][Full Text] [Related]
18. DNA interstrand cross-linking and cytotoxicity induced by chloroethylnitrosoureas and cisplatin in human glioma cell lines which vary in cellular concentration of O6-alkylguanine-DNA alkyltransferase.
Beith J; Hartley J; Darling J; Souhami R
Br J Cancer; 1997; 75(4):500-5. PubMed ID: 9052400
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer.
Clemons M; Ranson M; Margison JM; El Teraifi H; Griffiths A; Kelly J; Morris CQ; Howell A; Margison GP
Int J Cancer; 2003 Feb; 103(5):686-92. PubMed ID: 12494480
[TBL] [Abstract][Full Text] [Related]
20. Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Middleton MR; Kelly J; Goodger S; Thatcher N; Margison GP
Cancer Chemother Pharmacol; 2000; 45(1):15-20. PubMed ID: 10647496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
